A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
NRG Oncology
Institut Cancerologie de l'Ouest
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
Cambridge University Hospitals NHS Foundation Trust
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Yale University
M.D. Anderson Cancer Center